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To elucidate the role of human herpesvirus (HHV)-6 and -7 (HHV-7) in pityriasis rosea (PR), we measured their DNA
load in plasma, peripheral blood mononuclear cells (PBMC), and tissues using a calibrated quantitative real-time PCR
assay. We also studied HHV-6- and HHV-7-specific antigens in skin by immunohistochemistry and anti-HHV-7 neu-
tralizing activity using a syncytia-inhibition test. Plasma and PBMC were obtained from 31 PR patients (14 children, 17
adults), 12 patients with other dermatites, and 36 blood donors. Skin biopsies were obtained from 15 adults with PR
and 12 with other dermatites. HHV-6 and HHV-7 DNA were detected in 17% and in 39% of PR plasmas, respectively, but
in no controls. HHV-7 viremia was associated with a higher PBMC load and, in adults, with systemic symptoms. HHV-
7, but not HHV-6, levels in PBMC were higher in PR patients than in controls. HHV-6 and HHV-7 antigens were found
only in PR skin (17% and 67% of patients analyzed, respectively), indicating a productive infection. Syncytia-neu-
tralizing antibodies were found in PR patients and controls, but their titers were lower in patients with HHV-7 viremia.
These data conﬁrm the causal association between PR and active HHV-7 or, to a lesser extent, HHV-6 infection.
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Pityriasis rosea (PR) is a common, acute, self-limiting pap-
ulosquamous skin disorder. Some of its clinical and epide-
miological features suggest the pathogenic role of an
infectious agent (Allen et al, 1995). In 1997, a link between
PR and the reactivation of human herpesvirus (HHV)-7 in-
fection, a ubiquitous b-herpesvirus, was first suggested by
two of us (F. D. and A. R.) (Drago et al, 1997a, b). Contrast-
ing results were, however, obtained in subsequent studies:
several authors were unable to confirm the original findings
(Kempf et al, 1999; Kosuge et al, 2000; Karabulut et al,
2002) both in adults and children with PR (Chuh and Peiris,
2001), whereas others suggested that reactivation of HHV-7
and, in some cases HHV-6, may occur in PR (Yasukawa
et al, 1999; Tanaka-Taya et al, 2000). More recently, addi-
tional evidence in support of the involvement of HHV-7 and/
or HHV-6 in PR came from the detection of herpesvirus-like
particles in PR lesional skin (Drago et al, 2002), as well as
from a study by Watanabe et al (2002), who concluded that
PR is associated with active systemic co-infection with both
HHV-6 and HHV-7.
Unfortunately, most studies used qualitative molecular
approaches, such as nested PCR (Drago et al, 1997b;
Yasukawa et al, 1999; Watanabe et al, 1999, 2002; Kosuge
et al, 2000), which, in the case of highly diffused agents like
herpesviruses, cannot provide conclusive evidence for an
etiological link. This is particularly true when simple inde-
pendent epidemiological markers, such as the anti-HHV-6
and anti-HHV-7 IgG antibody titers, are virtually useless
given their high seroprevalence in healthy humans (Clark,
2000) and the partial antigenic cross-reactivity existing
among herpesviruses (Efstathiou et al, 1988).
Stronger evidence is provided, instead, by bona fide
calibrated quantitative real-time PCR (CQ-PCR) approaches
that are particularly suited for comparing the pathogen load
among different cohorts of individuals and different spec-
imens of the same patient, and are less prone to technical
artifacts. In this respect, three of us (F. B., P. L., and M. M.)
have developed a sensitive and accurate CQ-PCR ap-
proach (Locatelli et al, 2000; Broccolo et al, 2002, 2003) that
has been used, in this study, to assess the HHV-6 and HHV-
7 DNA load in peripheral blood mononuclear cells (PBMC),
plasma, and skin lesions of different cohorts of individuals.
PR was studied in both children and adults. The expression
of specific HHV-6 and HHV-7 antigens in skin lesions and
the presence of anti-HHV-7 neutralizing antibodies (Nab) in
the sera of patients and controls were investigated as com-
plementary independent approaches.
Results
Detection of HHV-6 and HHV-7 DNA in plasma and blood
cells HHV-6 and HHV-7 plasma viremia, which is a specific
marker of active infection, was detected in a significant
Abbreviations: CQ-PCR, calibrated quantitative real-time PCR;
HHV, human herpesvirus; IHC, immunohistochemistry; Mab,
monoclonal antibodies; Nab, neutralizing antibodies; PBMC, pe-
ripheral blood mononuclear cells; PR, pityriasis rosea
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proportion of PR patients (five of 31 and 12 of 31, respec-
tively), but in none of the healthy blood donors and of the
patients with other inflammatory diseases (Table I). Plasma
viremia for both HHV-6 and HHV-7 was co-detected in two
adult patients with PR. Overall, DNA of one or both viruses
was found in the plasma of 15 of 31 (48%) of the patients
with PR. The frequency of detection of HHV-6 and HHV-7
DNA (26 of 31 and 28 of 31, respectively) was not signif-
icantly different in PBMC from PR patients compared with
other inflammatory diseases (four of 12 and nine of 12, re-
spectively) and in blood donors (13 of 36 and 31 of 36,
respectively), even though detectable levels of HHV-6 were
more often seen among PR patients (Table I).
Again, the frequency of HHV-6 (one of 14 children and four
of 17 adults; p¼ 0.38) and HHV-7 DNA (six of 14 children and
six of 17 adults; p¼1) detection in plasma and PBMC (11 of
14 children and 15 of 17 adults for HHV-6, p¼ 1; 13 of 14
children and 13 of 17 adults for HHV-7, p¼0.79) was similar
in both pediatric and adult patients with PR.
Detection of HHV-7 and HHV-6 in skin samples Skin
specimens were positive for HHV-7 DNA in a significant
proportion of PR patients (10 of 12 vs zero of 12; p¼ 0.01),
but in none of the patients with other inflammatory diseases
(Table I). By contrast, the presence of HHV-6 DNA was not
significantly higher in the skin of PR compared with other
inflammatory diseases (seven of 12 vs one of 12; p¼ 0.21)
(Table I). Overall, DNA of one or both viruses was found in
11 of 12 (92%) of the skin biopsies tested, with a frequent
co-detection of both viruses (six of 12%, 50%).
Expression of the HHV-7 pp85 antigen was detected
by immunohistochemistry (IHC) in eight of 12 (67%) skin
samples, indicating the presence of a productive infection
(Fig 1b–f). In contrast, HHV-6 p41 antigen expression was
documented in only two of 12 (17%) of the PR skin biopsy
specimens (Table II). Overall, HHV-6 or HHV-7 antigens were
expressed in nine of 12 (75%) of the PR skin biopsy sam-
ples. HHV-7 and HHV-6 antigen-positive cells appeared to
be located mainly in the perifollicular and papillary dermis
(Fig 1e, f), with the exception of one patient in whom HHV-7
pp85 was also found in rare epidermal cells (Fig 1b). None
of the control skin specimens, obtained from 12 patients
affected by other cutaneous diseases, was positive for
HHV-6 and only one expressed HHV-7 antigens. All the
positivities observed by IHC were confirmed by detecting
the appropriate viral DNA in the tissue (Table II). The fre-
quency of HHV-6 and HHV-7 DNA detection by PCR was
higher than by IHC (seven of 12 vs two of 12; p¼0.41 and
10 of 12 vs eight of 12; p¼ 0.75, respectively), but all PCR-
negative samples were also IHC negative. HHV-6 pp41-ex-
pressing cells were observed together with a few HHV-7
pp85 antigen-positive cells only in one patient who was
PCR positive for both viruses in the tissue but not in the
plasma.
Viral load of HHV-6 and HHV-7 in clinical samples A
quantitative calibrated real-time PCR assay was used for
the accurate quantification of HHV-6 and HHV-7 viral load in
clinical specimens. Cellular DNA contamination was low in
all plasma samples (median, 200 cellular genome equivalent
per mL), thus ruling out the possibility that plasma viremia
was because of the destruction of latently infected cells
during sample manipulation. DNA from PBMC and tissues
samples was considered valuable if the reference CCR5
copy number in each PCR reaction was higher than 105
(corresponding to 5  104 cells), whereas DNA from plasma
Table I. HHV-6 and HHV-7 plasma viremia and cellular load in PBMC and skin from patients and controls
Subjects
No. of
individuals
HHV-6 TaqMan assay HHV-7 TaqMan assay
No. (%) of
positive
samples
No. of genome equivalents No. (%) of
positive
samples
No. of genome equivalents
 106 cells or mL Median  106 cells or mL Median
PR
Plasmaa 31 5/31 (16) o10–2.6  106 50 12/31 (39) o10–150 40
PBMC 31 26/31 (84) o10–9  106 35 28/31 (90) o10–6200 100
Skin 15 7/12 (58) o10–370 90 10/12 (83) o10–4.2  103 175
Inflammatory diseasesb
Plasma 12 0/12 (0) o15c 0/12 (0) o15
PBMC 12 4/12 (33) 10–25 20 9/12 (75) 10–75 60
Skind 12 1/12 (8) o15 0/12 (0) o15
Blood donors
Plasma 36 0/36 (0) o20 0/36 (0) o20
PBMC 36 13/36 (36) 10–50 30 31/36 (81) 10–725 60
aIncluding 14 pediatric and 17 adult patients.
bIncluding patients with atopic dermatitis, acute eczema, drug eruption or erythroderma, acute and chronic urticaria.
cFor negative samples the highest cut-off value is reported.
dAdults only.
HHV, human herpesvirus; PBMC, peripheral blood mononuclear cells; PR, pityriasis rosea.
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samples was considered valuable if the calibrator recovery
percentage was higher than 30%. The analysis of the am-
plification kinetics of the calibrator DNA allowed the pres-
ence of PCR inhibitors to be excluded (data not shown) and
to determine, for each negative sample, a specific cut-off
value for viral DNA detection, which varied between 10 and
35 genome equivalents per mL (Table II).
The level of plasma viremia ranged between 10 and 150
genome equivalents per mL for HHV-7 and between 10 and
2.6  106 for HHV-6 (Table I); however, a high viral load for
HHV-6 was only observed in a single adult patient (#17),
who had 2.6  106 and 4200 viral genome equivalents per
mL on two subsequent samples (Table II). No significant
differences were observed between adults and children with
PR (data not shown) as well as among patients infected with
a single virus or co-infected (patients #7 and #13, Table II).
Among PR patients, the PBMC viral load of HHV-7 was
significantly higher than the HHV-6 load (mean, 917 vs 137
genome equivalents per 106 cells; p¼0.037). The HHV-7
DNA load differed significantly between PR patients and
patients with other inflammatory diseases or healthy blood
donors, whereas the HHV-6 load in PBMC did not (Fig 2).
Remarkably, HHV-7 DNA load was significantly increased
in those patients who showed detectable HHV-7 plasma
viremia (mean, 2500 vs 535 genome equivalents per 106
cells; p¼0.003). Likewise, the skin HHV-7 DNA load was
higher than the HHV-6 one (mean, 741 vs 116 genome
equivalents per 106 cells), especially in patients with meas-
urable HHV-7 viremia (mean, 1100 vs 357 genome equiv-
alents per mL). Interestingly, only the HHV-7 load was
measurable in the tissues of patients who had detectable
plasma viremia for both viruses.
Correlation between anti-HHV-7 serum neutralizing ac-
tivity, HHV-7 plasma load, and clinical manifesta-
tions Bona fide syncytia formation was demonstrated
using the CD4þ T cell line Sup T1 as a target following
infection with an HHV-7 viral stock containing 106 cell cul-
ture infectious doses (CCID50) per mL. All the human sera
screened were found to contain syncytia-neutralizing activ-
ity at variable titers. A Gaussian distribution of HHV-7 Nab
was observed in both PR patients and in controls, peaking
at a titer of 320. Overall, the titers in control plasma were
comparable with those of PR patients, irrespective of the
clinical phase of the disease (Table III). Interestingly, when
PR patients were classified according to their HHV-7 plasma
load status, the mean Nab titers was significantly lower in
HHV-7 plasma load-positive patients than in HHV-7 plasma
load-negative patients (mean¼ 120 and 456, respectively;
p¼0.022) or in controls (mean, 305; po0.001). In addition,
in adult PR patients, HHV-7 and HHV-6 plasma viremia were
associated with the presence of systemic symptoms (10 of
20 vs zero of 13; p¼0.020), but not with the clinical phase of
the eruption. In fact, HHV-7 and/or HHV-6 DNA were de-
tected in 10 PR plasma samples, six of which were taken at
the first visit and four at the second one.
Discussion
Studies undertaken to assess the etiological role of HHV-7
and HHV-6 in human diseases, such as PR, have been se-
riously limited by the high prevalence of HHV-6 and HHV-7
infection in the human population (Clark, 2000). Although
several diagnostic methods have been developed, they of-
ten cannot distinguish between latent (clinically silent) and
active (clinically manifest) infection, which is critical to es-
tablish a causal relationship between these pathogens and
human diseases. Only bona fide quantitative methods,
which can measure the HHV-6 and HHV-7 viral load in tis-
sues, blood cells and, particularly, plasma and serum, per-
mit to assess the status of the infection. Three of us have
recently developed a fully controlled real-time PCR assay
for the measurement of cell-free pathogen DNA load in
body fluids, based on the addition of a synthetic DNA cal-
ibrator molecule prior to DNA extraction (Locatelli et al,
2000; Broccolo et al, 2002, 2003). The calibrator permits
each sample to be controlled for the presence of PCR in-
hibitors, allows the determination of cut-off values of sen-
sitivity for negative samples, and normalizes the positive
samples for the efficiency of DNA recovery. A similar ap-
proach, a TaqMan CQ-PCR assay, has been specifically
developed and used in this paper for the detection and
quantification of HHV-7 cell-free viremia and cellular viral
load.
Cell-free HHV-7 and HHV-6 DNA was detected in plasma
of 39% and 16% of patients, whereas none of the 36
healthy blood donors and 12 patients with other inflamma-
Figure 1
Detection and localization of human herpesvirus (HHV)-7 pp85
protein in skin lesions of four different patients. (a) Patient negative
for pp85. (b) Patient displaying positive cells in the epithelial layer. (c)
Patient showing absence of positive cells in the epithelium and the
presence of positive cells in the subcutaneous derma. (d) Higher mag-
nification of (c). (e) A fourth patient characterized by the presence of
positive cells in a perifollicular area. (f) Higher magnification of (e).
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Table II Clinical manifestation and virological parameters in adult PR patients
Patient
no.
Timing
(wk) Phase
No. of
lesions Relapse
Systemic
symptomsa
Viremia
Lesional skin
No. of genome
equivalents per mL
No. of genome
equivalents per 106 cells Viral antigens
HHV-6 HHV-7 HHV-6 HHV-7 HHV-6 HHV-7
1 1 EA 15 No Yes o13 o13 129 100  þ
3 M 40 Yes o10 o10
2 3 M o15 No Yes o10 o10 N/D N/D N/D N/D
11 PA 0 Yes o16 o16
3 2 M 2 No No o19 o19 20 820  þ
4 PA 4 No o27 o27
4 4 PA 30 No No o15 o15 N/D N/D N/D N/D
9 PA 0 No o20 o20
5 1 EA 50 No Yes o10 o10 370 128 þ þ
7 PA 50 Yes o17 40
6 3 M o10 No Yes o22 20 o10 60  þ
10 PA 0 No o25 o25
7 4 PA 25 Yes Yes o19 30 o10  þ
11 PA 0 Yes 50 40 1100
8 2 M 30 Yes Yes o10 o10 90 o10  
6 PA 0 No o20 o20
9 2 M 25 No No o12 o12 o10 o10  
6 PA 0 No o20 o20
10 6 PA o20 No No o14 o14 o10 50  þ
12 PA 0 No o10 o10
11 1 EA 12 Yes Yes o35 60 150 80  þ
6 PA 20 Yes o12 o12
12 6 PA 440 Yes Yes o13 25 10 4200  þ
12 PA 0 Yes o16 o16
13 2 M o10 No Yes o12 o12 o10 200  
12 PA 4100 Yes 25 20
14 4 PA 0 Yes No o23 o23 N/D N/D N/D N/D
10 PA o10 Yes o12 o12
15 3 M 4100 Yes Yes 20 o10 40 15 þ 
15 PA 4100 Yes N/A N/A
16 1 EA o15 No No o10 o10 N/A N/A N/A N/A
9 PA 0 No o12 o12
17 2 M 4100 No Yes 2.6  106 o13 N/A N/A N/A N/A
12 PA o15 Yes 4200 o10
aSystemic symptoms included: fatigue (in all patients), headache (in patients #1, 2, 7, 8, 11, 13, 15, 17), insomnia (in patients #2, 8, 15), arthromyalgia
(in patients #1, 5, 15), angina (in patients #5), irritability (in patients #13).
EA, early acute; PA, post-acute; M, manifest; N/A, not available; ND, not determined; HHV, human herpesvirus; PR, pityriasis rosea.
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tory skin diseases were positive. Our results confirm that
both HHV-7 and HHV-6 do not commonly replicate in
healthy individuals (Secchiero et al, 1995) as well as in pa-
tients affected by several acute or chronic cutaneous
inflammatory disorders. But we documented the active
replication of these herpesviruses in PR patients regard-
less of their age. Indeed, plasma viremia was detected in
adults and children with the same frequency for both virus-
es. We detected HHV-7 and HHV-6 DNA in PR plasma less
frequently than Watanabe et al (2002), who observed cell-
free viral DNA in 100% and 88% of serum samples, re-
spectively. This discrepancy could be related to the com-
bination of two variables, namely the type of biological
material studied and the different methods of investigation
used. In short, Watanabe et al (2002) evaluated only serum
samples positive for the amplification of the human b-globin
gene. This implies the presence, in the sample, of a signif-
icant amount of human genomic DNA likely because of the
destruction of leukocytes that occurred during the sample
manipulation or to a contamination with white blood cells. In
addition, qualitative approaches, such as highly sensitive
nested PCR techniques, cannot evaluate the weight of viral
DNA contaminations that originated from latently infected
cells. On the contrary, we used fully controlled quantitative
assays to measure, at the same time, viral load in both
PBMC and plasma, controlling to ensure that plasma sam-
ples were almost devoid of human DNA as well. Under these
conditions, the contribution to HHV-6 and HHV-7 detection
by viral DNA sequences belonging to latently infected PBMC
is meaningless. Therefore, only plasma DNA load measure-
ments can be considered a bona fide direct marker of viral
replication. Overall, the levels of HHV-6 and HHV-7 plasma
load proved to be similar and particularly low. This fact
makes detection of these viruses cumbersome and may help
to explain why the data of literature are discordant.
The significant Nab response against HHV-7 indicates
that, in PR patients, HHV-7 replication is associated with an
endogenous reactivation/reinfection, but not with a primary
HHV-7 infection, even in children. In this respect, our data are
in agreement with Watanabe et al’s (2002) observation, who,
finding HHV-7 and HHV-6 DNA in the saliva of all their pa-
tients, excluded a primary HHV-6/HHV-7 infection, since sal-
ivary gland cells act as a reservoir for HHV-7 and/or HHV-6
only in previously infected individuals (Sada et al, 1996).
Moreover, finding a neutralizing humoral response suggests
that, in PR, immune cell-mediated responses are probably
crucial in affecting HHV-7 reactivation, as it is the case in
other viral diseases. Despite this, the inverse correlation be-
tween titers of anti-HHV-7 neutralizing activity and detection
of HHV-7 in PR plasma may imply that humoral responses
contribute to limit viruses to spread, lowering their level in the
blood and controlling the extent of the disease. The obser-
vation that HHV-7 plasma viremia is strictly associated with
the severity of the symptoms strengthens such a hypothesis.
Remarkably, in all adult patients in whom plasma viremia
was detected, viral DNA and, in many instances, also viral-
encoded proteins belonging to HHV-6 or HHV-7 were con-
sistently found also in skin lesions. PCR and IHC yielded
slightly discordant results, however, probably because PCR
measures viral DNA regardless of the viral life cycle, where-
as IHC detects viral antigens express only during a given
moment of the virus replication cycle.
The expression in the skin lesions of the HHV-7 phospho-
protein complex pp85, a structural protein involved in the
late stage of infection (Kempf et al, 1998), and that of the
HHV-6 p41 nuclear phosphoprotein (Chang and Balachand-
ran, 1991) indicates that, in agreement with Watanabe et al’s
(2002) in situ hybridization data, a productive viral infection
is occurring. The significant difference found in the number
Figure 2
Peripheral blood mononuclear cells (PBMC) viral load of human
herpesvirus (HHV)-6 (closed circles) and HHV-7 (open circles) ex-
pressed as genome equivalents for 106 of cells. The bars indicate
the mean DNA load copy numbers in each group (pityriasis rosea (PR),
other inflammatory diseases, and blood donors) of TaqMan-positive
samples. The HHV-7 load in PBMC differed significantly among PR
patients, other inflammatory diseases, and blood donors (po0.05); by
contrast, the HHV-6 load in PBMC was not significantly different in any
of the groups considered.
Table III. Titration of syncytia-inhibitory antibodies to HHV-7 in human sera
PR subjects
No. of
samples tested
Titers of syncytia-inhibitory antibodies in serum
20 40 80 160 320 640 1280
Children 14 2a 3 6 3
Adults 17 1 2 4 6 3 1
Other inflammatory diseases 12 2 6 4
Healthy adults 36 1 4 5 7 11 7 1
aNumber of patients with the indicated syncytia-inhibitory titer.
HHV, human herpesvirus; PR, pityriasis rosea.
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of pp85- and pp41-expressing skin biopsies (67% and
17%, respectively) strongly suggests that, in PR, productive
HHV-7 infection is more frequent than HHV-6 infection. This
finding is further confirmed by the higher percentage of
HHV-7 viremic patients as well as by the significant differ-
ence in PBMC load between the two viruses.
In contrast to Watanabe et al (2002), in our study, HHV-6
and HHV-7 dual infection occurred only in 6% of plasma
samples analyzed, although DNA sequences belonging to
both viruses were present in a significant fraction of the
tissue samples. We conclude, therefore, that, although pos-
sible, the HHV-7/HHV-6 interaction may not represent a
common pathogenic mechanism in PR patients. Interest-
ingly, in our dually infected patients, HHV-7 replication pre-
ceded the appearance of HHV-6, as indicated by the
presence of the isolated HHV-7 in the skin biopsy and, in
one case, also in the plasma sample obtained at the first
time-point, suggesting that HHV-7 replication may favor,
in vivo, HHV-6 reactivation. These data are in agreement
with the in vitro observation of a frequent reactivation of
endogenous HHV-6 in PBMC cultures exposed to HHV-7
ex vivo (Katsafanas et al, 1996). On the other hand, we
documented in three distinct cases the active replication of
HHV-6 alone, thus demonstrating that this agent may cause
a clinically indistinguishable disease.
In conclusion, we have demonstrated that HHV-7 and,
less frequently, HHV-6 are active during the early stage of
PR, suggesting that they might play, both in adults and in
children, an etiological role in this disease. In addition, we
have shown that HHV-6 and HHV-7 plasma load, a direct
marker of viral replication, is associated with the develop-
ment of systemic symptoms as well as with a significant
reduction of the humoral neutralizing response against
HHV-7, further suggesting that PR may be because of the
endogenous reactivation of HHV-7 or HHV-6 infection.
Material and Methods
Patients, samples collection/preparation Thirty-one consecu-
tive patients with PR, 17 adults and 14 children (median age: 39
and 9 y, respectively), were recruited between December 2001 and
December 2003 at the Section of Dermatology, University of Genoa
and at the Department of Pediatric Dermatology, University of Mi-
lan. All patients had the classical clinical findings of PR and were
otherwise healthy and immunocompetent. Among adults, 12 com-
plained of systemic symptoms during the course of PR. Systemic
symptoms had different degrees of severity and duration. In some
patients, severe symptoms were present from the prodromal
phase up to the resolution of the skin eruption and even beyond.
Fatigue was present in all patients, but other symptoms, such as
headache, insomnia, arthralgias, myalgias, pharyngitis, and irrita-
bility, were common as well.
The clinical status of the patients was defined as early acute
phase (within 1 wk from eruption), manifest phase (7–21 d from
eruption), and post-acute or convalescent phase (21 d from eruption).
This permitted the association between plasma viremia, the phase of
the disease, and clinical manifestations (presence or absence of
systemic symptoms, number of lesions, etc.) to be studied.
A total of 212 blood and tissue samples were tested assessing
both HHV-6 and HHV-7 DNA load. Blood samples were taken from
all 17 adult patients during the first visit and after a few weeks of
follow-up (median¼ 5, range¼ 1–15). At the first visit, most adult
patients consented to a punch-biopsy of lesional skin (15 of 17).
The skin biopsies were taken from secondary lesions, except in
one patient in whom the ‘‘herald’’ patch was taken. Biopsy samples
were included in TissueTek O.C.T. (Bayer Corporation, Pittsburgh,
Pennsylavania) and snap-frozen in iso-pentane/liquid nitrogen.
Specimens were immediately stored at 801C. PBMC, plasma,
and sera were also obtained from 14 children during the early/
manifest phase of the disease. Blood and tissue samples from 12
patients with other inflammatory disorders (atopic dermatitis, acute
eczema, drug eruptions, acute and chronic urticaria, psoriasis)
were studied as controls. In addition, blood samples were obtained
from 36 healthy blood donors.
The medical ethical committee of the Universities of Genoa and
Milan approved all the described studies. The study was conduct-
ed according to the Declaration of Helsinki principles. All patients
or the patients’ parents gave their written informed consent.
PBMC were isolated by density gradient centrifugation of
EDTA-treated whole blood. DNA was extracted from plasma and
PBMC by the phenol–chloroform protocol as previously described
(Locatelli et al, 2000). Plasma samples were subjected to high-
speed centrifugation (26,000  g, 60 min, 41C) to concentrate vir-
ions. Five to ten biopsy sections (10 mm thick), each parted from
the following by 100 mm, were pooled and DNA was extracted after
proteinase K digestion (10 mg per mL) in 400 mL of Tissue Buffer
(50 mM Tris-HCl, pH 8.0; 200 mM NaCl; 20 mM EDTA, pH 8.0; 1%
SDS) and incubated overnight at 561C.
Calibrated quantitative real-time PCR assays for HHV-6, HHV-
7 CQ-PCR-based assays were performed on an ABI PRISM 7700
SDS (Applied Biosystems, Foster City, California), as reported
elsewhere (Broccolo et al, 2002). Four independent TaqMan real-
time PCR assays were performed to detect HHV-6, HHV-7, cali-
brator, and a highly conserved fragment of the single-copy human
CCR5 gene; this quantitative detection system was used to quan-
tify the content of human genomic DNA both in plasma and in the
PBMC pellets (Broccolo et al, 2002; Biswas et al, 2003).
At least 1 mg of genomic DNA recovered from each PBMC pellet
was subjected to real-time PCR analysis. Serial dilutions of gen-
omic DNA purified from PBMC of blood donors were used to
generate a reference curve for CCR5 quantification.
Primers and probe for HHV-6 DNA load measurement were
previously described (Locatelli et al, 2000).
Primers TAQ 7C (50-AGCGGTACCTGTAAAATCATCCA-30) and
TAQ 7D (50-AACAGAAACGCCACCTCGAT-30) were selected using
Primer Express software (PE Biosystem, Foster City, California).
They amplify a 129 bp fragment of the minor capsid protein of
HHV-7 (from nucleotides 100483 to 100611; GeneBank accession
#AF 037218). A fluorogenic probe of 30 bp (50-ACCAGTGAGAA-
CATCGCTCTAACTGGATCA-30), complementary to an internal re-
gion 32 bp downstream of the forward primer, was designed as
well. An extensive search of several databases, including the
EMBL and GeneBank databases, indicated that neither the primers
nor the probe shared significant homology with other known nuc-
leotide sequences. The results were normalized using a synthetic
DNA calibrator molecule (104 copies per reaction), added to the
samples before the extraction step, to control the inter-sample
extraction efficiency and to monitor PCR artifacts. The calibrator
molecule was then co-amplified by real-time PCR with the HHV-6
and HHV-7 target sequences. The primers and the calibrator probe
were specifically selected to avoid cross-hybridization with HHV-6
and HHV-7 systems. All reactions were optimized to obtain the
best amplification kinetics under the same cycling conditions
(2 min at 501C, 15 min at 951C, and 40 cycles of 15 s at 951C and 1
min per cycle at 601C) and composition of the reaction mixture
as previously described (Broccolo et al, 2002). Each sample was
tested in triplicate and the mean value was calculated.
IHC assays for HHV-6 and HHV-7 Three to ten serial cryosections
(10 mm thick) were stained using hematoxylin and eosin (HE) (Bio-
Optica, Milano, Italy) for histological evaluation and, subsequently,
IHC for localization of HHV-6 or HHV-7 antigens. Three biopsy
samples (patients 2, 4, 14, Table II) were eliminated during a pre-
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liminary histological evaluation because they did not contain val-
uable material (complete absence of the epidermis).
Monoclonal antibodies (Mab) 9A5D12 (Chang and Balachand-
ran, 1991) against the HHV-6 p41 early/late protein, expressed in
the host cell nucleus and 5E1 (Foa` Tomasi et al, 1996; Stefan et al,
1997) against the HHV-7 pp85 protein, a cytoplasm-expressed
antigen, were applied. Briefly, in IHC endogenous peroxidase was
inhibited by applying 0.3% H2O2. Sections’ pre-incubation with
a suitable pre-immune serum blocked unspecific binding. After-
wards, the primary antibodies were incubated overnight at 41C and
revealed with a biotinylated antibody followed by avidin–biotin–
HRP complexes (ABC e´lite system, Vector, Vector Labs, Burling-
ton, California) and diaminobenzidine chromogen-developing so-
lution. For each patient, at least three HE and five to six IHC
sections were independently evaluated by two pathologists at light
microscope (BH2, Olympus, Melville, New York) and digital pic-
tures were taken with an Olympus C4040 zoom digital camera
(Olympus Europe, Planneg, Germany).
Syncytia-inhibition test To identify anti-HHV-7 Nab, a syncytia-
inhibition test was carried out, as previously described (Secchiero
et al, 1994), in all sera samples included in this study .
Briefly, 2  105 HHV-7-infected Sup-T1 cells were incubated
with serial 2-fold dilutions of the tested sera and then co-cultured
with 2  105 uninfected Sup-T1 cells in 24-well plates (Costar
Corning Costar, Miecourt, Switzerland) in a total volume of 1 mL.
The Nab titer was determined as the reciprocal of the highest di-
lution of sera that completely prevented giant cell formation. Sync-
ytia formation was scored at 20 and 40 h after co-cultivation.
Statistical analysis Fisher’s exact test was used to analyze the
significance of the different HHV-7 and HHV-6 prevalent in PR pa-
tients and controls, and the significance of the different prevalence
of clinical manifestations in viremic patients and non-viremic
patients. A two-tailed Student’s t-test was used to evaluate the
significance of the different viral loads in the various groups
of individuals considered and the different titers of HHV-7 Nab
present in PR patients and controls. A po0.05 value was con-
sidered to be statistically significant.
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